Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

e sale of assets recognized in conjunction with our transaction with Agrigenetics Inc., a wholly-owned subsidiary of The Dow Chemical Company, which was accounted for as a sale of our plant trait business.

Cash and cash equivalents, short-term and long-term marketable securities, investments held by Symphony Evolution, Inc. (a consolidated clinical development financing vehicle) and restricted cash and investments totaled $297.6 million at September 30, 2007, compared to $263.2 million at December 31, 2006.

Q3 2007 Business Highlights

* In mid-September, we submitted a data report for XL880 to our partner

GlaxoSmithKline (GSK), which had requested an accelerated review of

XL880. GSK has 90 days from the date of submission of the data report

for XL880 to determine whether it will select XL880 for further

clinical development and commercialization.

* We presented encouraging data from a phase 2 proof-of-concept trial of

XL647 as first-line therapy for non-small cell lung cancer (NSCLC) at

the IASLC World Conference on Lung Cancer in Seoul, South Korea. On

October 24, 2007, we presented updated data from this same trial at

the AACR-NCI-EORTC Conference, where investigators reported that over

68% of evaluable patients had a clinical benefit. Out of 34 evaluable

patients, there were 10 partial responses and 13 cases of stable

disease. Responses were observed in patients with and without

activating EGFR mutations, and the compound was generally well

tolerated.

* We retained the right to develop and commercialize XL647 after GSK

declined its option to further develop the compound. Having clarified

ownership of the compound, we have begun an aggressive development

program that calls for pivotal trials of XL647 to be initiated in the

first half of 2008.

* We ex
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2
... executives hold high expectations that information technology will reduce ... however.  Earley & Associates, the nation,s foremost information management ... series titled Digitization of the Healthcare Industry ... on Wednesday, May 4 from 1-2 p.m. ...
... 3, 2011 Talecris Biotherapeutics Holdings Corp. (NASDAQ: ... Chapel Hill, N.C., where four proposals were submitted to, and ... the company,s Board of Directors to hold office for a ... and until their successors are elected and qualified. The three ...
... Inc. (Nasdaq: NVAX ) will report financial results ... 2011, before the U.S. financial markets open.  The announcement will ... Stanley C. Erck, President and Chief Executive Officer, and other ... The webcast and conference call will be available ...
Cached Biology Technology:Earley & Associates Offers Two-Part Webinar Series on Challenges and Solutions to Digitization in Healthcare 2Earley & Associates Offers Two-Part Webinar Series on Challenges and Solutions to Digitization in Healthcare 3Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting 2
(Date:7/11/2014)... researchers at the National Institute of Standards and ... their work more effectively, they often prove that ... was the case recently for M. Lorna De ... the growing specialization of glycomics. Glycomics is the ... glycans that are attached to proteins and lipids ...
(Date:7/11/2014)... Ume University, Sweden, have explored two different ways ... sequence leading to the formation of oxygen molecules ... in the scientific journal Nature Communications . ... day synthetic catalysts for water oxidation, which are ... the direct storage of solar energy in fuels ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... Pathogens , Francisella tularensis , the cause of ... is considered a potential biological weapon because it is readily ... in humans. While a live attenuated vaccine strain has ... to understand the basis for its attenuated virulence. In ...
... Universitt Mnchen (TUM) under Prof. Peter Schieberle and at the ... edible fats and oils: Lard, butterfat, rapeseed oil and olive ... ate 500 grams of low-fat yoghurt enriched with one of ... supplement to their normal diet. "Olive oil had the ...
... series across both genders continue to remain alarmingly low ... patient education and increased public vaccine financing programs are ... Texas Medical Branch (UTMB). The researchers report ... published in Cancer, Human Vaccines & Immunotherapeutics ...
Cached Biology News:News tips from the journal mBio®, volume 4, issue 1 2Olive oil makes you feel full 2HPV vaccine trends point to failures in patient education, vaccine programs 2
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Request Info...
... ideal for both radioactive and nonradioactive labeling ... Provides five pre-mixed nucleotide solutions for flexibility ... 8 cpm/g control DNA using [-32P]-dCTP ... performance of the system Labels 1 ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Biology Products: